An article from
News roundup
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees in Missouri.
Published June 10, 2026
Getty Images
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.
546 words~2 min read
